doi:10.1155/2023/5827613 202
Luba Yammine, who ran the trial on exenatide and smoking cessation, described to JAMA Medical News how she became interested in this area: As a clinician, family nurse practitioner Luba Yammine, PhD, MSN, sees patients with substance use disorders, including many who smoke
#ClinicalPharmacology #Pharmacokinetics #PharmacyEducation #Pharmacotherapy #MedicalEducation To view or add a comment, sign in $NVO has started a Phase 1 trial for its new obesity drug candidate LX9851, developed with Lexicon Pharmaceuticals The drug is oral and works differently from current GLP-1 treatments, targeting fat metabolism and satiety signals The study will assess safety in overweight and obese patients, with results expected in Q1 2027 Lexicon receives a $10M milestone payment and could earn up to $1B plus royalties if successful #stocks #Investing To view or add a comment, sign in Sun Pharma joins semaglutide race with over 60% cheaper generic #Noveltreat (for weight-loss) will cost patients between Rs 3,490 and Rs 7,400, while #Sematrinity (for type-2 diabetes) monthly cost ranges between Rs 2,960 and Rs 4,790
Among patients with CKD and type 2 diabetes, vascular dysfunction, insulin resistance, and chronic inflammation are associated with an increased risk for dementia and Alzheimers disease
Let our medical team know youre interested in medical weight loss treatment
